Are Cell Therapy Leaders Losing Their Innovative Edge? Spotlight Series on Novartis, BMS, and Gilead (Kite)
Since the first US CAR-T approval in 2017, the cell therapy field has rapidly evolved with 5 additional CAR-Ts receiving FDA approval. Nevertheless, challenges surrounding TATs, cost, and patient access still remain. As such, companies are developing innovative strategies to overcome the challenges that the field is currently facing. In the upcoming six-part series, the Celltelligence team will analyze different innovative strategies which the cell therapy leaders (Novartis, BMS, and Gilead) are utilizing to remain competitive in this dynamic space. At the end of the series, Celltelligence will present a semi-qualitative analysis comparing the innovative strategies from Novartis, BMS, and Gilead (Kite).
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.